Independent fund research. Built on SEC filings.

How we research funds

ETF · Technology Sector · SPDR (State Street)

State Street(R) SPDR(R) S&P(R) Biotech ETF (XBI)

Ticker XBI · Index fund · · Holdings as of Jun 30, 2026

Expense ratio
0.35%$35/yr per $10k
5-yr return
−2.7%annualized
1-yr return
+35.8%as of Dec 2025
Net assets
$10.7Ball share classes
Holdings
161

Bottom line

Is XBI a good fund? The bottom line

XBI is an index technology sector ETF from SPDR (State Street).

Annual fees run 0.35% — about $35 a year on every $10,000 invested, cheaper than 90% of technology sector funds we track.

It returned +35.8% over one year, −2.7% a year over five years, +5.8% a year over ten (as of Dec 31, 2025, per its prospectus).

With $10.7 billion in net assets and 161 holdings, its largest position is State Street Global Advisors (5.9%) and the top 10 make up 18% of the portfolio.

What stands out

  • Low cost: cheaper than 90% of technology sector peers
  • Large and established ($10.7 billion)

What to watch

  • 5-year return in the bottom quarter of its category

Updated Nov 19, 2026

What XBI invests in

The State Street SPDR S&P Biotech ETF (the Fund) seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the biotechnology segment of a U.S. total market composite index.

In seeking to track the performance of the S&P Biotechnology Select Industry Index ? (the Index), the Fund employs a sampling strategy, which means that the Fund is not required to purchase all of the securities represented in the Index. Instead, the Fund may purchase a subset of the securities in the Index in an effort to hold a portfolio of securities with generally the same risk and return characteristics of the Index. The quantity of holdings in the Fund will be based on a number of factors, including asset size of the Fund. Based on its analysis of these factors, SSGA Funds Management, Inc. (SSGA FM or the Adviser), the investment adviser to the Fund, either may invest the Fund's assets in a subset of securities in the Index or may invest the Fund's assets in substantially all of the securities represented in the Index in approximately the same proportions as the Index, as…

From the fund's prospectus (filed Oct 26, 2026).

XBI performance

Fund calendar-year total returns, 2015–2025 2015: +13.6%; 2016: −15.4%; 2017: +43.7%; 2018: −14.9%; 2019: +32.2%; 2020: +48.2%; 2021: −20.5%; 2022: −25.8%; 2023: +7.5%; 2024: +1.1%; 2025: +35.8% +14% 2015 −15% 2016 +44% 2017 −15% 2018 +32% 2019 +48% 2020 −21% 2021 −26% 2022 +8% 2023 +1% 2024 +36% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
XBI+35.8%−2.7%+5.8%
Technology Sector median+24.0%+10.0%+16.7%

Source: Fund prospectus, as of Dec 31, 2025

Full XBI performance history →

What XBI costs

On a $10,000 investment, XBI's 0.35% expense ratio costs about $35 a year. The prospectus estimates $443 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.

See the full XBI fee table →

XBI top 10 holdings

#Holding% of fund
1State Street Global Advisors5.87%
2Apogee Therapeutics Inc1.49%
3Moderna Inc1.41%
4Twist Bioscience Corp1.41%
5Oruka Therapeutics Inc1.38%
6Kymera Therapeutics Inc1.36%
7Viking Therapeutics Inc1.30%
8Praxis Precision Medicines Inc1.29%
9Erasca Inc1.27%
10Revolution Medicines Inc1.20%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 18% of the fund. See all top 25 holdings and asset mix →

Alternatives to XBI

More funds like XBI →

XBI FAQ

What is the expense ratio of XBI?
XBI's expense ratio is 0.35%, which works out to about $35 a year for every $10,000 invested. The prospectus estimates total costs of $443 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is XBI a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 90% of technology sector peers; large and established ($10.7 billion); 5-year return in the bottom quarter of its category. This is general information, not personalized advice.
What does XBI hold?
XBI's largest holdings are State Street Global Advisors (5.9%), Apogee Therapeutics Inc (1.5%), Moderna Inc (1.4%), Twist Bioscience Corp (1.4%), Oruka Therapeutics Inc (1.4%). It holds 161 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is XBI's 5-year return?
XBI returned −2.7% a year over the five years ending Dec 31, 2025, and +5.8% a year over ten years. Past performance does not guarantee future results.
Who manages XBI?
XBI is offered by SPDR (State Street) through Spdr Series Trust.